Kimberly Sirk
Psychiatric/Mental Health · Merrillville, INNPI 1114281466
Payments from drug & device makers
Across 677 payments — averaging $23.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Teva Pharmaceuticals USA, Inc.$986
- Axsome Therapeutics, Inc.$965
- Johnson & Johnson$960
- Supernus Pharmaceuticals, Inc.$933
- plus $8K from 28 others
What the payments were for
- Food & beverage$15,39698%
- Education$3672%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 142 | $2,503 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 40 | $1,681 |
| Teva Pharmaceuticals USA, Inc. | 36 | $986 |
| Axsome Therapeutics, Inc. | 27 | $965 |
| Johnson & Johnson | 39 | $960 |
| Supernus Pharmaceuticals, Inc. | 47 | $933 |
| Neurocrine Biosciences, Inc. | 28 | $866 |
| Otsuka America Pharmaceutical, Inc. | 29 | $812 |
| Alkermes, Inc. | 31 | $799 |
| Tris Pharma Inc | 33 | $760 |
| Corium, LLC | 26 | $596 |
| Lundbeck LLC | 34 | $567 |
| Vanda Pharmaceuticals Inc. | 17 | $525 |
| Takeda Pharmaceuticals U.S.A., Inc. | 30 | $491 |
| Jazz Pharmaceuticals Inc. | 19 | $434 |
| Idorsia Pharmaceuticals US Inc | 12 | $279 |
| E.r. Squibb & Sons, L.L.C. | 8 | $200 |
| Harmony Biosciences LLC | 5 | $180 |
| Bausch Health US, LLC | 10 | $173 |
| Merck | 11 | $159 |
| Sunovion Pharmaceuticals Inc. | 15 | $153 |
| Avadel CNS Pharmaceuticals, LLC | 6 | $148 |
| Ironshore Pharmaceuticals Inc. | 6 | $139 |
| Almatica Pharma LLC | 6 | $111 |
| Noven Therapeutics, LLC | 4 | $65 |
| Collegium Pharmaceutical, Inc. | 3 | $63 |
| OWP Pharmaceuticals, Inc. | 3 | $61 |
| Eisai Inc. | 3 | $43 |
| Adlon Therapeutics L.p. | 2 | $26 |
| Neos Therapeutics, LP | 1 | $25 |
| Noven Pharmaceuticals, Inc. | 1 | $17 |
| Braeburn Inc. | 1 | $15 |
| Indivior Inc. | 1 | $15 |
| Avanir Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$960
- CAPLYTA$900
- Auvelity$475
- VRAYLAR$326
- REXULTI$226
- Quillivant$125
- Quillichew ER$125
- Dyanavel XR$125
- ABILIFY ASIMTUFII$125
- ABILIFY MAINTENA$125
- Austedo XR$115
- QUVIVIQ$114
- SPRAVATO$110
How this compares
$15,763 in reported general payments places this provider in the 95th percentile of 729 psychiatric/mental health providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 24 | $144,317 |
| VraylarCariprazine Hcl | 71 | $115,462 |
| Aripiprazole | 92 | $25,833 |
| TrintellixVortioxetine Hydrobromide | 33 | $23,185 |
| RexultiBrexpiprazole | 15 | $21,709 |
| FetzimaLevomilnacipran Hcl | 16 | $16,831 |
| VyvanseLisdexamfetamine Dimesylate | 23 | $10,758 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 54 | $4,429 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 15 | $3,765 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 28 | $3,021 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 39 | $2,909 |
| Bupropion XlBupropion Hcl | 117 | $2,524 |
| Lurasidone Hcl | 16 | $2,306 |
| Quetiapine Fumarate | 132 | $2,212 |
| Vilazodone Hcl | 16 | $2,184 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $986 | $144,31724 claims |
| AbbVieVraylar, Fetzima | $2,503 | $132,29387 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $491 | $33,94356 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $812 | $21,70915 claims |
| Almatica Pharma LLCSertraline Hcl | $111 | $672129 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 729 psychiatric/mental health providers in Indiana.
Other psychiatric/mental health in Merrillville
- Gerald LewisMerrillville$336K
- Helen MunnMerrillville$13K
- Sandra SperlingMerrillville$8K
- Jazmine QuinteroMerrillville$6K
- Brooke KempfTerre Haute$1.1M
- Lauren LutzColumbus$320K
- Sonya RuedlingerIndianapolis$134K
- Trina GreenwaldMarion$107K
- Paul DuncanJeffersonville$46K
- Morgan StamperConnersville$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.